Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?

Metabolomics changes in COVID-19 predict acute patient outcomes and suggest a role for a bioenergetic crisis. Thus, metabolomics changes in COVID-19 may serve as a biomarker and provide insight into pathogenic mechanisms and pharmacologic targets. https://bit.ly/2XkJeU8

Detalles Bibliográficos
Autores principales: Hartsell, Emily M., Gillespie, Mark N., Langley, Raymond J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Editorials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542864/
https://www.ncbi.nlm.nih.gov/pubmed/34675049
http://dx.doi.org/10.1183/13993003.02417-2021
_version_ 1784589517511983104
author Hartsell, Emily M.
Gillespie, Mark N.
Langley, Raymond J.
author_facet Hartsell, Emily M.
Gillespie, Mark N.
Langley, Raymond J.
author_sort Hartsell, Emily M.
collection PubMed
description Metabolomics changes in COVID-19 predict acute patient outcomes and suggest a role for a bioenergetic crisis. Thus, metabolomics changes in COVID-19 may serve as a biomarker and provide insight into pathogenic mechanisms and pharmacologic targets. https://bit.ly/2XkJeU8
format Online
Article
Text
id pubmed-8542864
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-85428642021-10-26 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Hartsell, Emily M. Gillespie, Mark N. Langley, Raymond J. Eur Respir J Editorials Metabolomics changes in COVID-19 predict acute patient outcomes and suggest a role for a bioenergetic crisis. Thus, metabolomics changes in COVID-19 may serve as a biomarker and provide insight into pathogenic mechanisms and pharmacologic targets. https://bit.ly/2XkJeU8 European Respiratory Society 2022-02-24 /pmc/articles/PMC8542864/ /pubmed/34675049 http://dx.doi.org/10.1183/13993003.02417-2021 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Editorials
Hartsell, Emily M.
Gillespie, Mark N.
Langley, Raymond J.
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
title Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
title_full Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
title_fullStr Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
title_full_unstemmed Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
title_short Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
title_sort does acute and persistent metabolic dysregulation in covid-19 point to novel biomarkers and future therapeutic strategies?
topic Editorials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542864/
https://www.ncbi.nlm.nih.gov/pubmed/34675049
http://dx.doi.org/10.1183/13993003.02417-2021
work_keys_str_mv AT hartsellemilym doesacuteandpersistentmetabolicdysregulationincovid19pointtonovelbiomarkersandfuturetherapeuticstrategies
AT gillespiemarkn doesacuteandpersistentmetabolicdysregulationincovid19pointtonovelbiomarkersandfuturetherapeuticstrategies
AT langleyraymondj doesacuteandpersistentmetabolicdysregulationincovid19pointtonovelbiomarkersandfuturetherapeuticstrategies

Ejemplares similares